2025 Annual Business Report

A specialty
vaccine company

Valneva at a glance

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.

img-small
2025 Highlights

2025 Highlights

2025 demonstrated Valneva’s resilience and dedication to progress. We achieved significant milestones across our development pipeline, including our mid– and late-stage clinical assets.

Our vaccine pipeline

Our vaccine pipeline

We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best-, or only-in-class vaccine solutions.

Our strategy

Our strategy

Our strategy supports our vision to live in a world in which no one dies or suffers from a vaccine-preventable disease.

Our Global Operations

Our Global Operations

To develop, manufacture, and commercialize vaccines globally, Valneva maintains sites and affiliates in six countries.

Our Commercial Business

Our Commercial Business

Valneva commercializes its own vaccines against Japanese encephalitis, chikungunya and cholera, as well as third party-products, in key markets.